Inflammatory bowel disease: past, present, and future

por Sands, Bruce E.
Publicado 2007

Personalised Medicine with IL-23 Blockers: Myth or Reality?

por Gottlieb, Zoë S, Sands, Bruce E
Publicado 2021

Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management

por Johnson, F. Reed, Hauber, Brett, Siegel, Corey A., Hass, Steven, Sands, Bruce E.
Publicado 2010

Efficient augmentation and relaxation learning for individualized treatment rules using observational data

por Zhao, Ying-Qi, Laber, Eric B., Ning, Yang, Saha, Sumona, Sands, Bruce E.
Publicado 2019

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3

por Sands, Bruce E, Van Assche, Gert, Tudor, David, Akhundova-Unadkat, Gamar, Curtis, Rebecca I, Tan, Tjoeke
Publicado 2019

Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort

por Perler, Bryce, Ungaro, Ryan, Baird, Grayson, Mallette, Meaghan, Bright, Renee, Shah, Samir, Shapiro, Jason, Sands, Bruce E.
Publicado 2019

Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction T...

por Loftus, Edward V, Sands, Bruce E, Colombel, Jean-Frédéric, Dotan, Iris, Khalid, Javaria Mona, Tudor, David, Geransar, Parnia
Publicado 2020

Correction to: Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort

por Perler, Bryce K., Ungaro, Ryan, Baird, Grayson, Mallette, Meaghan, Bright, Renee, Shah, Samir, Shapiro, Jason, Sands, Bruce E.
Publicado 2020

Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease

por Wils, Pauline, Jairath, Vipul, Sands, Bruce E., Magro, Fernando, Reinisch, Walter, Rubin, David, Danese, Silvio, Baumann, Cédric, Peyrin‐Biroulet, Laurent
Publicado 2023

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association

por Kaplan, Gilaad G, Hubbard, James, Korzenik, Joshua, Sands, Bruce E, Panaccione, Remo, Ghosh, Subrata, Wheeler, Amanda J, Villeneuve, Paul J
Publicado 2010

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open

por Panaccione, Remo, Abreu, Maria T., Lazariciu, Irina, Mundayat, Rajiv, Lawendy, Nervin, Salese, Leonardo, Woolcott, John C., Sands, Bruce E., Chaparro, María
Publicado 2022

Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program

por Sandborn, William J., Sands, Bruce E., Vermeire, Séverine, Leung, Yvette, Guo, Xiang, Modesto, Irene, Su, Chinyu, Wang, Wenjin, Panés, Julian
Publicado 2022

Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis

por Sands, Bruce E., Joshi, Shashidhar, Haddad, Jonathan, Freudenberg, Johannes M., Oommen, Deepa Elizabeth, Hoffmann, Ethan, McCallum, Stewart W., Jacobson, Eric
Publicado 2015

Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Control...

por Atreja, Ashish, Khan, Sameer, Rogers, Jason D, Otobo, Emamuzo, Patel, Nishant P, Ullman, Thomas, Colombel, Jean Fred, Moore, Shirley, Sands, Bruce E
Publicado 2015

The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis

por Sands, Bruce E, Cheifetz, Adam S, Nduaka, Chudy I, Quirk, Daniel, Wang, Wenjin, Maller, Eric, Friedman, Gary S, Su, Chinyu, Higgins, Peter D R
Publicado 2019

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposu...

por Burmester, Gerd R, Nash, Peter, Sands, Bruce E, Papp, Kim, Stockert, Lori, Jones, Thomas V, Tan, Huaming, Madsen, Ann, Valdez, Hernan, Cohen, Stanley B
Publicado 2021

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease

por Lichtenstein, Gary R, Rutgeerts, Paul, Sandborn, William J, Sands, Bruce E, Diamond, Robert H, Blank, Marion, Montello, Jennifer, Tang, Linda, Cornillie, Freddy, Colombel, Jean-Frédéric
Publicado 2012

Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management

por Sands, Bruce E, Colombel, Jean-Frédéric, Ha, Christina, Farnier, Michel, Armuzzi, Alessandro, Quirk, Daniel, Friedman, Gary S, Kwok, Kenneth, Salese, Leonardo, Su, Chinyu, Taub, Pam R
Publicado 2020

Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease

por Feagan, Brian G., Sandborn, William J., Sands, Bruce E., Liu, Yan, Vetter, Marion, Mathias, Susan D., Huang, Kuan-Hsiang Gary, Johanns, Jewel, Germinaro, Matthew, Han, Chenglong
Publicado 2023

Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies

por Sands, Bruce E, Feagan, Brian G, Hunter Gibble, Theresa, Traxler, Kristina A, Morris, Nathan, Eastman, William J, Schreiber, Stefan, Jairath, Vipul, Long, Millie D, Armuzzi, Alessandro
Publicado 2023